ImmunoPrecise Antibodies Ltd. has announced its financial results for the fiscal year ending April 30, 2025. The company achieved a record-breaking revenue of $24.5 million, marking a significant achievement for the year. In the fourth quarter, the company reported its highest-ever revenue of $7.0 million. The fourth quarter also saw a record Adjusted EBITDA of ($0.3) million, indicating improved operating efficiency. The company achieved a gross margin of 64% in the fourth quarter, the strongest margin performance since the third quarter of the fiscal year 2021. Additionally, the BioStrand segment experienced remarkable growth of over 180% in fiscal year 2025, with gross margins approaching 90%.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。